Overview

This trial is active, not recruiting.

Condition wrinkles
Treatment ha idf ii plus or ha idf ii
Phase phase 4
Sponsor LG Life Sciences
Start date November 2013
End date February 2014
Trial size 62 participants
Trial identifier NCT02340078, LG-HACL011

Summary

The objective of this study was to evaluate the efficacy and safety of HA IDF II plus (with lidocaine) injected in the nasolabial fold compared to HA IDF II (without lidocaine).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Active Comparator)
cross-linked HA filler
ha idf ii plus or ha idf ii
(Experimental)
cross-linked HA filler with lidocaine
ha idf ii plus or ha idf ii

Primary Outcomes

Measure
① Proportion of the subjects with at least 10mm difference in VAS pain scale scores within the subject (VAS of the control device - VAS of the test device) immediately after treatment with the investigational devices
time frame: day 0

Eligibility Criteria

Female participants from 30 years up to 60 years old.

Inclusion Criteria: 1. Women aged between 30 and 60 2. Those whose wrinkles in the treatment area (nasolabial fold) correspond to Stage 3 or 4 in the 5-stage Wrinkle Severity Rating Scale (WSRS) symmetrically 3. Those who were informed on the purpose, method, and effect etc. of this study and signed the informed consent form 4. Those who fell under any of the following 3 cases: 1. Surgically sterile women 2. Women in menopause over 2 years from the last menstruation, aged at least 45 3. Among the women meeting neither of a nor b, those who agreed to use at least 2 contraception methods specified below (one of the barrier methods must be included) until 14 days after the last treatment with the investigational device - Barrier methods: Condom, diaphragm, cervical cap (pessary), spermicide - Hormonal methods: Pills, injection (depot), skin patch, hormonal implant (Implanon), vaginal ring - Intrauterine devices (IUDs): Cooper IUD (Loop), hormonal IUD (Mirena) - Natural methods: Basic body temperature, ovulation period, coitus interruptus, abstinent Exclusion Criteria: 1. Those with a skin disease (skin infection, eczema, psoriasis, rosacea, herpes etc.) in the lower 2/3 part of the face in which the wrinkle evaluation may be affected 2. Patients with a malignant tumor recognized medically important and considered as potentially affecting the clinical study 3. Women in pregnancy or lactation 4. Those with the bilirubin level exceeding 1.5 times of the upper limit of normal or the ALT/AST level exceeding 2.5 times of the upper limit of normal 5. Those with the confirmed infection of syphilis or HIV 6. Those who had an anticoagulant therapy or antiplatelet therapy within 2 weeks prior to Visit 1 (screening) 7. Those who used a topical preparation (steroid, retinoid) in the facial area within 4 weeks prior to Visit 2 (randomization ) 8. Those who experienced a deep chemical peeling or a procedure judged as potentially affecting the clinical study within 3 months prior to Visit 2 (randomization) 9. Those who experienced a non-permanent filler procedure or a cosmetic surgery in the face within 9 months prior to Visit 2 (randomization) 10. Those who had an implantation procedure with a permanent substance (silicone, PAAG, PMMA, CaHA etc.) in the treatment area (nasolabial fold ) 11. Those currently with a streptococcal disease 12. Those with a history of severe allergy or hypersensitivity (anaphylaxis) judged as potentially affecting the clinical study 13. Those with a history of hypertrophic scar or keloid 14. Those with a history of bleeding disorder 15. Those with a hypersensitivity to the investigational device of this clinical study or lidocaine 16. Those who refused to agree not to use a local or systemic pain-relieving agent or other pain-relieving method (e.g.: ice pack) from the midnight of the treatment day with the investigational device through the post-measurement of the last VAS pain scale 17. Those who had participated in another clinical study within 1 month prior to Visit 1 (screening) 18. Those judged by the investigator as ineligible for this clinical study

Trial information was received from ClinicalTrials.gov and was last updated in January 2015.
Information provided to ClinicalTrials.gov by LG Life Sciences.